Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090161 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
A Phase 2 study of Hypertension and Uncontrolled Hypertension, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT07090161 is a Phase 2 study of Hypertension and Uncontrolled Hypertension that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 240 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07090161, a Phase 2 study of Hypertension and Uncontrolled Hypertension, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Conditions Studied
Interventions
- DRUG Placebo
- DRUG iloperidone
Study Locations (20)
California
- Vanda Investigative Site - Chula Vista
- Vanda Investigative Site - Dublin
- Vanda Investigative Site - Valencia
- Vanda Investigative Site - Walnut Creek
Arizona
- Vanda Investigative Site - Phoenix
- Vanda Investigative Site - Tempe
- Vanda Investigative Site - Tucson
Florida
- Vanda Investigative Site - Doral
- Vanda Investigative Site - Fort Myers
Illinois
- Vanda Investigative Site - Oak Brook
- Vanda Investigative Site - Tinley Park
Kansas
- Vanda Investigative Site - El Dorado
- Vanda Investigative Site - Wichita
New York
- Vanda Investigative Site - Mount Kisco
- Vanda Investigative Site - Rochester
Georgia
- Vanda Investigative Site - Columbus
Kentucky
- Vanda Investigative Site - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07090161
The ClinicalTrials.gov registry entry for NCT07090161 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07090161 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07090161 about?
NCT07090161 is a clinical study titled "Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension". A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
What is the current status of trial NCT07090161?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-09-15. Estimated completion is 2026-11.
What conditions does trial NCT07090161 study?
This clinical trial studies the following conditions: Hypertension, Uncontrolled Hypertension.
What interventions are being tested in trial NCT07090161?
The interventions under investigation include: Placebo (DRUG), iloperidone (DRUG).
Who is sponsoring clinical trial NCT07090161?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090161 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.